Characteristics of a large sample of candidates for permanent ventricular pacing included in the Biventricular Pacing for Atrio-ventricular Block to Prevent Cardiac Desynchronization Study (BioPace)

Abstract

To the best of our knowledge, this sample is a representative source of description of the general profile of European pacemaker recipients who require predominant VP. Patients' characteristics included advanced age, predominantly male gender, preserved left ventricular systolic function, high-grade AV block, narrow QRS complex, and atrial tachyarrhythmias, the latter being present in nearly one-fourth of the cohort.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

“…Można temu zapobiegać za pomocą CRT, co może poprawić wyniki leczenia [274,275,277,290]. Nie zaobserwowano różnic w punktach końcowych między CRT a stymulacją RV w analizie podgrup z badania RAFT [267] oraz u pacjentów bez HFrEF w badaniu BioPACE [291]. Z kolei to CRT bardziej niż stymulacja prawokomorowa jest zalecana u pacjentów z HFrEF, niezależnie od klasy NYHA, u których istnieją wskazania do stymulacji komorowej w celu obniżenia chorobowości, przy czym brakuje dowodów na zmniejszenie śmiertelności.…”

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

“…274,275,277,290 However, a difference in outcome was not observed between CRT and RV pacing in a subgroup analysis of RAFT 267 or in patients without HFrEF in BioPACE. 291 On balance, CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class who have an indication for ventricular pacing in order to reduce morbidity, although no clear effect on mortality was observed. Patients with HFrEF who have received a conventional pacemaker or an ICD and subsequently develop worsening HF with a high proportion of RV pacing, despite OMT, should be considered for upgrading to CRT.…”

Reducing Ventricular Pacing Frequency in Patients With Atrioventricular Block

“…42 In the BIOPACE study, the mean LV ejection fraction was 55%±12% and the trial included only a low proportion of patients with complete AVB or PR interval above 230 ms. The mean follow-up was 67 months.…”